Ozmosi | Obatoclax Drug Profile

Product Description

Mechanisms of Action: BCL2 Inhibitor

Novel Mechanism: No

Modality: Small Molecule

Route of Administration: Intravenous

FDA Designation: None *

Approval Status: Not Approved

Approved Countries: None

Approved Indications: None

Known Adverse Events: None

Company: Gemin X
Company Location:
Company CEO:
Additonal Commercial Interests: None

Countries in Clinic:

Phase 3: Small Cell Lung Cancer

Trial	Phase	Trial Status	Disease	Primary Completion Date
C41601/3099	P3	Withdrawn	Small Cell Lung Cancer	2016-05-01
NCI-2009-00254	P1	Terminated	Prolymphocytic B-Cell Leukemia\|Chronic Lymphoid Leukemia\|Lymphocytic Chronic B-Cell Leukemia\|Prolymphocytic Leukemia	2013-07-01
NCI-2011-01936	P1	Terminated	Chronic Myeloid Leukemia\|Sezary Syndrome\|Lymphomatoid Granulomatosis\|Plasmablastic Lymphoma\|Leukemia, Plasma Cell\|Chronic Lymphoid Leukemia\|Lymphoma, Non-Hodgkin\|Blast Crisis\|Myelogenous, Chronic, BCR-ABL Positive Leukemia\|Diffuse Large B-Cell Lymphoma\|Acute Myeloid Leukemia\|Precursor T-Cell Lymphoblastic Leukemia-Lymphoma\|Large-Cell Anaplastic Lymphoma\|Burkitt Lymphoma\|Hairy Cell Leukemia\|Precursor Cell Lymphoblastic Leukemia-Lymphoma\|Extranodal NK-T-Cell Lymphoma\|Large-Cell Immunoblastic Lymphoma\|Precursor B-Cell Lymphoblastic Leukemia-Lymphoma\|Acute Lymphoid Leukemia\|T-Cell Peripheral Lymphoma\|Immunoblastic Lymphadenopathy\|Mycosis Fungoides\|T-Cell Leukemia\|T-Cell Cutaneous Lymphoma\|Intraocular Lymphoma\|Lymphocytic Chronic B-Cell Leukemia	2013-04-01
NCI-2011-02536	P2	Withdrawn	Follicular Lymphoma\|B-Cell Marginal Zone Lymphoma\|Lymphoma, Non-Hodgkin\|Mantle-Cell Lymphoma	2012-04-01

Date	Type	Title
04/16/2024	PubMed	Differential susceptibility of cells infected with defective and intact HIV proviruses to killing by obatoclax and other small molecules.
03/30/2024	PubMed	An integrated framework for prognosis prediction and drug response modeling in colorectal liver metastasis drug discovery.
12/18/2023	PubMed	Molecular dynamics simulations assisted investigation of phytochemicals as potential lead candidates against anti-apoptotic Bcl-B protein.
09/28/2021	News Article	Genprex Strengthens Management Team with Appointments of Industry Leaders Mark S. Berger, M.D. as Chief Medical Officer and Hemant Kumar, Ph.D. as Chief Manufacturing and Technology Officer
05/11/2020	News Article	Acer Therapeutics to Develop Emetine as Potential COVID-19 Treatment in Collaboration with National Center for Advancing Translational Sciences, One of the National Institutes of Health
03/13/2019	News Article	Karuna Bolsters Research and Development Team